These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 15149145)

  • 21. Optimizing dendritic cell-based immunotherapy for cancer.
    Zhong H; Shurin MR; Han B
    Expert Rev Vaccines; 2007 Jun; 6(3):333-45. PubMed ID: 17542749
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dendritic cells in vaccination therapies of human malignant disease.
    Reichardt VL; Brossart P; Kanz L
    Blood Rev; 2004 Dec; 18(4):235-43. PubMed ID: 15501552
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dendritic cell-tumor fusion vaccines for renal cell carcinoma.
    Avigan D
    Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6347S-52S. PubMed ID: 15448029
    [TBL] [Abstract][Full Text] [Related]  

  • 24. On the road to a tumor cell vaccine: 20 years of cellular immunotherapy.
    Yannelli JR; Wroblewski JM
    Vaccine; 2004 Nov; 23(1):97-113. PubMed ID: 15519713
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes against murine colon cancer: a comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells.
    Yasuda T; Kamigaki T; Nakamura T; Imanishi T; Hayashi S; Kawasaki K; Takase S; Ajiki T; Kuroda Y
    Oncol Rep; 2006 Dec; 16(6):1317-24. PubMed ID: 17089056
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Idiotype vaccination in multiple myeloma induced a reduction of circulating clonal tumor B cells.
    Rasmussen T; Hansson L; Osterborg A; Johnsen HE; Mellstedt H
    Blood; 2003 Jun; 101(11):4607-10. PubMed ID: 12576327
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Towards therapeutic vaccines for colorectal carcinoma: a review of clinical trials.
    Mosolits S; Nilsson B; Mellstedt H
    Expert Rev Vaccines; 2005 Jun; 4(3):329-50. PubMed ID: 16026248
    [TBL] [Abstract][Full Text] [Related]  

  • 28. DCs and CD40-activated B cells: current and future avenues to cellular cancer immunotherapy.
    Schultze JL; Grabbe S; von Bergwelt-Baildon MS
    Trends Immunol; 2004 Dec; 25(12):659-64. PubMed ID: 15530836
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dendritic cell-based cancer vaccination: quo vadis?
    Dauer M; Schnurr M; Eigler A
    Expert Rev Vaccines; 2008 Sep; 7(7):1041-53. PubMed ID: 18767953
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Future of idiotypic vaccination for B-cell lymphoma.
    de Cerio AL; Inogés S
    Expert Rev Vaccines; 2009 Jan; 8(1):43-50. PubMed ID: 19093772
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preparation of fully activated dendritic cells capable of priming tumor-specific cytotoxic T lymphocytes in patients with metastatic cancer using penicillin-killed streptococcus pyogenes (OK432) and anti-CD40 antibody.
    Kontani K; Teramoto K; Ozaki Y; Sawai S; Tezuka N; Ishida H; Kajino K; Fujino S; Yamauchi A; Taguchi O; Kannagi R; Yokomise H; Ogasawara K
    Oncol Rep; 2007 Apr; 17(4):895-902. PubMed ID: 17342333
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [In vitro anti-myeloma effects induced by myeloma idiotype-protein pulsed dendritic cell vaccine].
    Zhang M; Yin XR; Luo YY; Lin X; Wang MC; He PC; Li J; Guo GL; Cai RH; Liu YL
    Zhonghua Xue Ye Xue Za Zhi; 2005 Oct; 26(10):593-7. PubMed ID: 16532967
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New understanding of immunological mechanisms.
    Saalmüller A
    Vet Microbiol; 2006 Oct; 117(1):32-8. PubMed ID: 16701965
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cellular immunotherapy with dendritic cells in cancer: current status.
    Nencioni A; Brossart P
    Stem Cells; 2004; 22(4):501-13. PubMed ID: 15277696
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-Gal-mediated targeting of human B lymphoma cells to antigen-presenting cells: a potential method for immunotherapy using autologous tumor cells.
    Manches O; Plumas J; Lui G; Chaperot L; Molens JP; Sotto JJ; Bensa JC; Galili U
    Haematologica; 2005 May; 90(5):625-34. PubMed ID: 15921377
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A pilot clinical trial of vaccination with dendritic cells pulsed with autologous tumor cells derived from malignant pleural effusion in patients with late-stage lung carcinoma.
    Chang GC; Lan HC; Juang SH; Wu YC; Lee HC; Hung YM; Yang HY; Whang-Peng J; Liu KJ
    Cancer; 2005 Feb; 103(4):763-71. PubMed ID: 15637694
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cancer vaccines for established cancer: how to make them better?
    Andrews DM; Maraskovsky E; Smyth MJ
    Immunol Rev; 2008 Apr; 222():242-55. PubMed ID: 18364006
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vaccination: role in metastatic melanoma.
    Pilla L; Valenti R; Marrari A; Patuzzo R; Santinami M; Parmiani G; Rivoltini L
    Expert Rev Anticancer Ther; 2006 Aug; 6(8):1305-18. PubMed ID: 16925496
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Taming cancer by inducing immunity via dendritic cells.
    Palucka AK; Ueno H; Fay JW; Banchereau J
    Immunol Rev; 2007 Dec; 220():129-50. PubMed ID: 17979844
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Advances in specific immunotherapy for prostate cancer.
    Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
    Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.